12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Plasma-derived Alpha-1 Antitrypsin: Phase II started

Omni Bio said investigators at the University of Michigan Cancer Center began an open-label, U.S. Phase II trial to evaluate twice-weekly, 60 mg/kg AAT for 4...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >